Aldeyra Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Aldeyra Therapeutics has a total shareholder equity of $85.1M and total debt of $15.3M, which brings its debt-to-equity ratio to 18%. Its total assets and total liabilities are $117.3M and $32.2M respectively.
Key information
18.0%
Debt to equity ratio
US$15.28m
Debt
| Interest coverage ratio | n/a |
| Cash | US$72.74m |
| Equity | US$85.10m |
| Total liabilities | US$32.22m |
| Total assets | US$117.32m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 137's short term assets ($116.7M) exceed its short term liabilities ($17.2M).
Long Term Liabilities: 137's short term assets ($116.7M) exceed its long term liabilities ($15.1M).
Debt to Equity History and Analysis
Debt Level: 137 has more cash than its total debt.
Reducing Debt: 137's debt to equity ratio has reduced from 28.3% to 18% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 137 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 137 has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 1.2% each year.